The Medical Research Council has announced that its Millennium medal for 2013 is to be shared by two illustrious biochemists.

Both Sir Greg Winter and Sir Philip Cohen are no strangers to the receipt of awards. Indeed both started by winning the Colworth Medal (sponsored by Unilever) from the Biochemical Society for an outstanding young British biochemist.

Phil was one of the earliest recipients – in 1977. While Greg won it in 1986.

They also have in common that they have spent virtually their entire research career in one place.

**Phil Cohen** was one of the founders of the Department of Biochemistry in Dundee, and was largely responsible for turning it from scratch into one of the most successful laboratories in Europe, and one of the largest employers in the City of Dundee. No department has produced more Colworth medal winners.

He started his work on phosphorylation during his post doctoral work in Ed Fischer’s laboratory in Seattle, and since then has never looked back.

The subtle interlinking of kinases and phosphatases, and their effect on cell regulation have been grist to his mill for more than 30 years. He and colleagues have shown the effects in numerous metabolic processes.

**A phosphorylation cascade involves the phosphorylation of a protein which then becomes an active kinase, and this in turn can phosphorylate other kinases activating them, and on and on. At each step, there is a very large amplification of the original signal so that a very small initial signalling event can be converted into a very large response.**

He was made a Fellow of the Royal Society in 1984 and knighted in 1998.

Greg Winter started in protein sequencing in the days before DNA took over. He moved on from his interest in enzymes to the structures of antibodies. He worked out how to engineer antibodies themselves, and most importantly, domains within them which were nonetheless biologically active.

He set up Cambridge Antibody Technology more than 20 years ago. It remains one of the most successful academic spin out companies in the life sciences in the UK.

**HUMIRA**, an antibody against TNF (Tumour Necrosis Factor) alpha is now marketed by Abbott Laboratories, and has annual sales in excess of $1bn.

He has simultaneously received one of the Canada Gairdner Awards for 2013.

He was made a Fellow of the Royal Society in 1990, and knighted in 2004. He has just taken over from Martin Rees as Master of Trinity College, Cambridge.

**Alan Malcolm**